Human Papillomavirus Type Distribution Among Patients with High Grade Cervical Dysplasia in Lafayette, Louisiana
Location
Center for Advanced Learning & Simulation (CALS)
Publication Date
May 2026
Start Date
8-5-2026 10:15 AM
End Date
8-5-2026 10:30 AM
Description
Objective: To evaluate the prevalence of high-grade cervical dysplasia-cervical intraepithelial neoplasia 2/3 (CIN 2/3)-and the associated presenting HPV genotypes. This study aims to determine what percentages of CIN 2/3 can be attributed to HPV 16, 18, and the Other high risk HPV group and assess potential associations with HPV vaccination status in a population from Lafayette, Louisiana.
Methods: A retrospective chart review was conducted for patients who underwent colposcopy between July 2019 and January 2025 at a single academic institution. Patients diagnosed with high-grade cervical dysplasia (CIN 2/3) were included. HPV genotype results and Gardasil vaccination status were extracted and analyzed. Chi-square tests and logistic regression were used to assess associations between HPV genotype, vaccination status, and severity of dysplasia. The primary outcome was the percentage of high-grade dysplasia associated with various HPV strains. The secondary outcome was to assess HPV vaccination rates.
Results: Among 257 patients reviewed, 137 (53.3%) had CIN 3. HPV 16 was the most common genotype (41.4%), followed by Other high-risk HPV types (35.6%) and HPV 18 (23.0%). Only 27.4% of CIN 3 patients were fully vaccinated, while 47.4% were never vaccinated. No significant associations were found between HPV genotype or vaccination status and dysplasia severity (p > 0.05). Age-stratified analysis revealed a non-significant trend toward increasing prevalence of non-16/18 genotypes with advancing age (p = 0.097).
Conclusions: HPV 16 remains the dominant genotype in high-grade dysplasia, but a substantial proportion of cases are due to non-16/18 types. Vaccination rates remain suboptimal in this population. No significant association was found between genotype or vaccination status and severity of dysplasia, though trends suggest evolving genotype patterns with age. These findings support continued emphasis on HPV vaccination and genotype surveillance.
Recommended Citation
Taskov, Viktoria DO; Nguyen, Anh BS; Patel, Hinali BS; and Provost, Holly MD, "Human Papillomavirus Type Distribution Among Patients with High Grade Cervical Dysplasia in Lafayette, Louisiana" (2026). Dept. of Obstetrics & Gynecology Resident Research Day. 6.
https://digitalscholar.lsuhsc.edu/obgyn_rd/2026/presentations/6
Human Papillomavirus Type Distribution Among Patients with High Grade Cervical Dysplasia in Lafayette, Louisiana
Center for Advanced Learning & Simulation (CALS)
Objective: To evaluate the prevalence of high-grade cervical dysplasia-cervical intraepithelial neoplasia 2/3 (CIN 2/3)-and the associated presenting HPV genotypes. This study aims to determine what percentages of CIN 2/3 can be attributed to HPV 16, 18, and the Other high risk HPV group and assess potential associations with HPV vaccination status in a population from Lafayette, Louisiana.
Methods: A retrospective chart review was conducted for patients who underwent colposcopy between July 2019 and January 2025 at a single academic institution. Patients diagnosed with high-grade cervical dysplasia (CIN 2/3) were included. HPV genotype results and Gardasil vaccination status were extracted and analyzed. Chi-square tests and logistic regression were used to assess associations between HPV genotype, vaccination status, and severity of dysplasia. The primary outcome was the percentage of high-grade dysplasia associated with various HPV strains. The secondary outcome was to assess HPV vaccination rates.
Results: Among 257 patients reviewed, 137 (53.3%) had CIN 3. HPV 16 was the most common genotype (41.4%), followed by Other high-risk HPV types (35.6%) and HPV 18 (23.0%). Only 27.4% of CIN 3 patients were fully vaccinated, while 47.4% were never vaccinated. No significant associations were found between HPV genotype or vaccination status and dysplasia severity (p > 0.05). Age-stratified analysis revealed a non-significant trend toward increasing prevalence of non-16/18 genotypes with advancing age (p = 0.097).
Conclusions: HPV 16 remains the dominant genotype in high-grade dysplasia, but a substantial proportion of cases are due to non-16/18 types. Vaccination rates remain suboptimal in this population. No significant association was found between genotype or vaccination status and severity of dysplasia, though trends suggest evolving genotype patterns with age. These findings support continued emphasis on HPV vaccination and genotype surveillance.
Comments
Advisor: Holly Provost MD